The SARS-CoV ferret model in an infection–challenge study

Abstract Phase I human clinical studies involving therapeutics for emerging and biodefense pathogens with low incidence, such as the severe acute respiratory syndrome coronavirus (SARS-CoV), requires at a minimum preclinical evaluation of efficacy in two well-characterized and robust animal models....

Full description

Saved in:

Bibliographic Details
Published in:	Virology (New York, N.Y.) Vol. 374; no. 1; pp. 151 - 163
Main Authors:	Chu, Yong-Kyu, Ali, Georgia D, Jia, Fuli, Li, Qianjun, Kelvin, David, Couch, Ronald C, Harrod, Kevin S, Hutt, Julie A, Cameron, Cheryl, Weiss, Susan R, Jonsson, Colleen B
Format:	Journal Article
Language:	English
Published:	United States Elsevier Inc 25-04-2008
Subjects:	Animal model Animals Antibodies, Viral - blood Body Temperature Disease Models, Animal Ferret Ferrets Infectious Disease Leukocyte Count Lung - pathology Lung - virology Lymphocyte Count Male Mustela putorius furo Nasal Cavity - virology Neutralization Tests Pharynx - virology SARS coronavirus SARS Virus - physiology SARS-CoV Severe Acute Respiratory Syndrome - immunology Severe Acute Respiratory Syndrome - pathology Severe Acute Respiratory Syndrome - physiopathology Severe Acute Respiratory Syndrome - virology Animal model Ferret SARS-CoV
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Abstract Phase I human clinical studies involving therapeutics for emerging and biodefense pathogens with low incidence, such as the severe acute respiratory syndrome coronavirus (SARS-CoV), requires at a minimum preclinical evaluation of efficacy in two well-characterized and robust animal models. Thus, a ferret SARS-CoV model was evaluated over a period of 58 days following extensive optimization and characterization of the model in order to validate clinical, histopathological, virological and immunological endpoints. Ferrets that were infected intranasally with 103 TCID50 SARS-CoV showed higher body temperature (2–6 d.p.i.), sneezing (5–10 d.p.i.), lesions (5–7 d.p.i.) and decreased WBC/lymphocytes (2–5 d.p.i.). SARS-CoV was detected up to 7 d.p.i. in various tissues and excreta, while neutralizing antibody titers rose at 7 d.p.i. and peaked at 14 d.p.i. At 29 d.p.i., one group was challenged with 103 TCID50 SARS-CoV, and an anamnestic response in neutralizing antibodies was evident with no detectable virus. This study supports the validity of the ferret model for use in evaluating efficacy of potential therapeutics to treat SARS.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Feature-3 ObjectType-Undefined-2
ISSN:	0042-6822 1096-0341
DOI:	10.1016/j.virol.2007.12.032